Enliven Therapeutics, Inc. ELVN
44.75
(0.42)
(0.93%)
as of 25 Sep
- Market cap
- $3.3B
- P/E
- 0.0×
Follow ELVN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
32.95 | 28.66 | 40.32 | 64.07 |
Net Debt/EBITDA |
18.84 | 13.53 | 16.43 | 24.40 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.66 | 0.53 | 0.82 | 0.57 | |
Capex/Depreciation |
0.00 | 2.11 | 0.00 | (0.19) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.21) | (0.28) | (0.31) | (0.28) | |
Cash per Share |
7.69 | 8.16 | 7.20 | 13.53 | |
Shareholders Equity per Share |
7.67 | 8.11 | 7.22 | 13.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.67 | 8.11 | 7.22 | 13.53 | |
Free Cash Flow |
(13.28) | (15.62) | (19.29) | (18.63) | |
Working Capital |
468.03 | 458.31 | 451.65 | 893.18 | |
Capital Expenditures |
0.00 | 0.21 | — | (0.10) | |
Net Current Asset Value |
467.93 | 458.31 | 451.65 | 892.27 | |
| Other line items | |||||
Quick Ratio |
32.60 | 27.92 | 39.38 | 63.21 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.28) | (0.31) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.22 | 1.75 | 1.60 | 1.36 | |
Average Assets |
398.15 | 400.96 | 383.71 | 707.06 | |
Average Common Equity |
382.26 | 384.72 | 370.83 | 691.81 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates